Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.73 |
| ▸ | MEN1 | O00255 | 10/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.67 |
| ▸ | XDH | P47989 | 7/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.67 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.67 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.67 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.67 |
| ▸ | RECQL | P46063 | 5/20 | 0.67 |
| ▸ | APP | P05067 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118117 | 0.91 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| Quercetin-3'-O-Phosphate SCHEMBL30814958 | 0.91 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| Quercetin-3'-O-Phosphate SCHEMBL118113 | 0.91 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| Quercetin-3'-O-Phosphate SCHEMBL30299021 | 0.91 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| SCHEMBL3807705 | 0.90 | CYP1A2 (0.75) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| SCHEMBL19197066 | 0.88 | CYP1A2 (0.65) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| SCHEMBL19470004 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| SCHEMBL13056264 | 0.85 | CYP1A2 (0.69) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| Quercetin SCHEMBL4473370 | 0.85 | MEN1 (0.74) | CYP1A2CYP1A1CYP1B1MEN1KMT2A | |
| Tamarixetin SCHEMBL892776 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2355814-A2 | PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS | Limerick BioPharma, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| EP-2182957-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2010042886-A2 | PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | claimed |
| WO-2009018338-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-10421768-B2 | Method of biotransformation of benzopyrone compounds into the corresponding phosphate-conjugated derivatives | NATIONAL TAIWAN UNIVERSITY (TW) | 2019-09-24 | — | — | US | disclosed |
| US-10421768-B2 | Method of biotransformation of benzopyrone compounds into the corresponding phosphate-conjugated derivatives | NATIONAL TAIWAN UNIVERSITY (TW) | 2019-09-24 | — | — | US | disclosed |
| US-20170305944-A1 | METHOD OF BIOTRANSFORMATION OF BENZOPYRONE COMPOUNDS INTO THE CORRESPONDING PHOSPHATE-CONJUGATED DERIVATIVES | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-10-26 | — | — | US | disclosed |
| US-20170305944-A1 | METHOD OF BIOTRANSFORMATION OF BENZOPYRONE COMPOUNDS INTO THE CORRESPONDING PHOSPHATE-CONJUGATED DERIVATIVES | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-10-26 | — | — | US | disclosed |
| US-20170305944-A1 | METHOD OF BIOTRANSFORMATION OF BENZOPYRONE COMPOUNDS INTO THE CORRESPONDING PHOSPHATE-CONJUGATED DERIVATIVES | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-10-26 | — | — | US | disclosed |
| EP-2424541-A2 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2355814-A2 | PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS | Limerick BioPharma, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2182957-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010042886-A2 | PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158031-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158007-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009018338-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | CYP1A2 832/4885CYP1A1 802/4885CYP1B1 991/4885 |
| US-10421768-B2 | Method of biotransformation of benzopyrone compounds into the corresponding phosphate-conjugated derivatives | BPGM, PNKP, DHPS | CYP1A2 82/4885CYP1A1 171/4885CYP1B1 123/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | CYP1A2 3381/4885CYP1A1 4274/4885CYP1B1 3991/4885 |
| US-20170305944-A1 | METHOD OF BIOTRANSFORMATION OF BENZOPYRONE COMPOUNDS INTO THE CORRESPONDING PHOSPHATE-CONJUGATED DERIVATIVES | BPGM, PNKP, DHPS | CYP1A2 82/4885CYP1A1 171/4885CYP1B1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.